SynthesisDiagnostic pathology2016

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.

Ja Seong Bae et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.